Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 657 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cervical Cancer Stage I Clear all
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

NCT00004097
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

NCT01188850
View directory record Official record
Conditions
Human Papillomavirus (HPV)
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 46 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 13, 2026, 11:38 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 13, 2026, 11:38 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions
Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT)
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Lenvatinib Pill, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 13, 2026, 11:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

NCT02058550
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Radiation Toxicity, Vaginal Cancer
Interventions
survey administration, computer-assisted intervention, telephone-based intervention
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

NCT03032250
View directory record Official record
Conditions
Caregiver, Malignant Head and Neck Neoplasm, Paranasal Sinus Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal SCC, Recurrent Paranasal Sinus Squamous Cell Carcinoma
Interventions
Communication Intervention, Watch video, Module completion of the Prepare to Care kit, Quality-of-Life Assessment, Survey Administration, Salivary cortisol collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

NCT02065973
View directory record Official record
Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Interventions
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Biological
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Port Jefferson, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 13, 2026, 11:38 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 13, 2026, 11:38 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 13, 2026, 11:38 PM EDT
Terminated Phase 1 Interventional

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
View directory record Official record
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Not applicable Interventional

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

NCT00019201
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology, bronchoscopic and lung imaging studies, bronchoscopy, comparison of screening methods, endoscopic biopsy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 13, 2026, 11:38 PM EDT
Terminated Phase 1 Interventional

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT02438995
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Interventions
Intraarterial Cetxuimab (Erbitux)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

NCT00033657
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
23
States / cities
Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 13, 2026, 11:38 PM EDT
Withdrawn Phase 2 Interventional

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

NCT03146039
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 13, 2026, 11:38 PM EDT
Recruiting Phase 1 Interventional

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
Interventions
MQ719, Pembrolizumab
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

NCT00622674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Simultaneous Integrated Boost (SIB) in Esophageal Cancer

NCT01102088
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

NCT00077051
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, cytochlor, tetrahydrouridine, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

NCT04555837
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Interventions
Alisertib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 13, 2026, 11:38 PM EDT
Completed Not applicable Interventional

Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer

NCT00086242
View directory record Official record
Conditions
Cervical Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
Psychosocial Telephone Counseling (PTC)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 13, 2026, 11:38 PM EDT
Completed No phase listed Observational

Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes

NCT00460356
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Lymphadenectomy
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
18
States / cities
Orange, California • Sylmar, California • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 13, 2026, 11:38 PM EDT
Terminated Phase 2 Interventional

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib, conventional surgery, enzyme inhibitor therapy, neoadjuvant therapy, protein tyrosine kinase inhibitor therapy, surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 13, 2026, 11:38 PM EDT